Mablink Bioscience, the next generation ADC company, raises €4 Million to move forward its ADC pipeline targeted at cancers with high unmet medical needs
LYON, France, April 27, 2021 /PRNewswire/ — Mablink Bioscience, a company developing the next generation of antibody-drug conjugates (ADC) through its proprietary hydrophilic drug-linker PSARlink™ platform, announces today the completion of a €4 Million Seed financing round led by Elaia…
Comments Off on Mablink Bioscience, the next generation ADC company, raises €4 Million to move forward its ADC pipeline targeted at cancers with high unmet medical needs